Loading...

LGND LIGAND PHARMACEUTICALS INC Investments/Divestments 8-K Filing

LGND

LGND

LIGAND PHARMACEUTICALS INC

(LGND)

2023 8-K

Financial Results Announced

Investor Update

Financial Results

Credit Agreement Update

Convertible Notes Offering

Financial Statements

Merger of Equals

Financial Statements

Merger Agreement

Financial Results

Financial Results

Financial Results Announcement

Departure of Directors or C...

Acquisition of APEIRON Biol...

Amendment to Credit Agreement

Acquisition of APEIRON Biol...

FDA Approval for Ohtuvayre

FDA Approval and Phase 3 Re...

Annual Meeting Results

Acquisition of Royalty Rights

Agreement for Royalty Right...

Bylaws Amendment

Financial Results Announcement

FDA Approval for ZELSUVMI

Expansion of Partnership

Amendment to Earnings Release

Financial Results Announcement

Acquisition of Royalty and ...

Credit Facility Agreement

Appointment of Director

Merger Agreement

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

External Links:

Ligand Pharmaceuticals has expanded its partnership with Palvella Therapeutics to accelerate the development of QTORIN rapamycin for the treatment of Microcystic Lymphatic Malformations, with Palvella receiving a $5 million upfront payment and Ligand receiving increased royalties and a security interest in royalties and patents.

AI Assistant

LIGAND PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.